ORIGINAL RESEARCH article

Front. Cell Dev. Biol., 24 July 2025

Sec. Embryonic Development

Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1587052

miR-383-3p and miR-6951-3p activate cell proliferation through the regulation of genes related to hypertelorism

  • 1. Department of Orthodontics and Pediatric Dentistry, School of Dentistry, University of Michigan, Ann Arbor, MI, United States

  • 2. Department of Diagnostic & Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, United States

Article metrics

View details

1

Citations

1,3k

Views

246

Downloads

Abstract

Hypertelorism, characterized by an abnormal increase in the distance between the eyes, is often associated with various congenital birth defects. While there is increasing evidence suggesting common underlying mechanisms for hypertelorism, the role of microRNAs (miRNAs)—short noncoding RNAs that suppress target genes by inhibiting translation and degrading mRNA—in the condition’s pathogenesis remains unclear. This study aimed to identify the miRNAs associated with hypertelorism in mice. By searching the Mouse Genome Informatics (MGI) database and reviewing full-text references, we identified a total of 31 genes potentially related to hypertelorism. Advanced bioinformatics analyses revealed nine miRNAs that may regulate these genes. We experimentally evaluated candidate miRNAs in assays of cell proliferation and target gene regulation in primary cells isolated from developing frontonasal process mouse embryonic frontonasal mesenchymal and O9-1 cells, a murine neural crest cell line. Our findings indicated that overexpression of either miR-383-3p or miR-6951-3p stimulated cell proliferation, whereas miR-7116-3p and miR-124-3p did not have this effect. Additionally, we confirmed that miR-383-3p and miR-6951-3p regulated the expression of a set of hypertelorism-related genes in a dose-dependent manner. These results suggest that miR-383-3p and miR-6951-3p play significant roles in the development of hypertelorism.

1 Introduction

The frontonasal prominence (FNP) forms the midfacial region, including the forehead, nose, philtrum of the upper lip, and primary palate. It starts to develop at 4 weeks of gestation in humans and embryonic day (E) 9.5 in mice and the FNP forms a pair of medial and lateral nasal prominences (MNP and LNP), which develop into the philtrum, primary palate and nasal pits, and fuses with the maxillary prominence by 6 weeks of gestation in humans and E12.5 in mice (Som and Naidich, 2013; Suzuki et al., 2016). Various signaling pathways, including sonic hedgehog (SHH) and fibroblast growth factor (FGF), play crucial roles in FNP outgrowth through tissue-tissue interactions (Suzuki et al., 2016; Cobourne et al., 2009).

In humans, facial morphological variants are evaluated in a dysmorphology exam with precise anthropometric facial measurements and cephalometric analyses (Myers et al., 2020). Hypertelorism (a.k.a. orbital hypertelorism) is characterized by an abnormally increased distance between the orbits, yielding more than the 95th percentile on normative anthropometric values in inner canthal distance, outer canthal distance, and interpupillary distance (Cohen et al., 1995). Hypertelorism is often associated with other congenital birth defects such as midline facial cleft, craniosynostosis syndromes (e.g., Apert syndrome), and encephaloceles (Kimonis et al., 2007). Morphometric analyses show a strong association between facial morphology and/or variations in genetic architecture in humans (Sero et al., 2019; Claes et al., 2018; Knol et al., 2022; Xiong et al., 2019; White et al., 2021). For instance, interorbital distance is significantly associated with human genomic variants at a single base position as single nucleotide polymorphisms (SNPs) at RPS12, EYA4 (6p21.2; rs5880172) (Claes et al., 2018), and STX18-AS1 (4p16.2; rs13117653) (White et al., 2021). Recent studies show that microRNAs (miRNAs), non-coding short single RNAs with 18–25 nucleotides, are involved in the cause of various birth defects through spatiotemporal gene regulation (Iwaya et al., 2023). miRNAs inhibit the expression of multiple target genes (Huang et al., 2020) and play a role in craniofacial development in humans and mice (Iwaya et al., 2023). FNP development is affected by the expansion of the forebrain as well as cell proliferation, apoptosis, and migration. Hypertelorism is caused by any disruption in an orbital movement towards the midline and hypergrowth of the region between eyes during frontonasal development. This study aims to identify specific miRNAs potentially associated with hypertelorism in mice. In this study, we focus on increased cell proliferation related to overgrowth of the region between eyes, one of the potential mechanisms of hypertelorism. This step could significantly advance our understanding of this condition and potentially lead to new treatment strategies.

2 Materials and methods

2.1 Mouse genome informatics database search

The Mouse Genome Informatics (MGI) database (https://www.informatics.jax.org) was used to search genes related to hypertelorism in mice, with search terms ‘hypertelorism’ and ‘wide distance between eyes.’ The genes from the MGI search were further evaluated through the references cited.

2.2 Bioinformatic analysis

miRTarbase, miRbase, MirDB, and TargetScan were used to predict miRNA-target gene regulation, as previously described (Suzuki et al., 2018a). The significance level of the shared genes between miRNA-target genes and genes related to hypertelorism was examined with Fisher’s exact test (Riol et al., 2020). The Bonferroni collection was used for multiple test correction (Benjamini et al., 2001). MGI clustering analysis, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and the Gene Ontology (GO) enrichment analysis were conducted using ShinyGO 0.77 (http://bioinformatics.sdstate.edu/go/) for biological process (BP), cell component (CC), and molecular function (MF) (Ge et al., 2020; Luo and Brouwer, 2013) for applying the biological pathway. Significantly enriched categories for the genes were filtered with a false discovery rate (FDR)-adjusted p-value <0.05 in a hypergeometric test and at least four genes related to hypertelorism. Excessively general GO terms below hierarchical level 4 were excluded.

2.3 Cell culture

C57BL/6J mice were ostained from The Jackson Laboratory. Primary mouse embryonic frontonasal mesenchymal (MEFM) cells were isolated from the frontonasal process of C57BL/6J embryos on E10.5. The frontonasal process was dissected in sterile Dulbecco’s Phosphate-Buffered Saline (D-PBS) and then suspended into single-cell suspensions using 0.25% trypsin and 0.05% EDTA for 10 min at 37°C in an atmosphere containing 5% CO2. The animal protocol (PRO00011979) was approved by the Animal Welfare Committee (AWC) and the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan. MEFM cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose (Sigma-Aldrich) supplemented with 10% fetal bovine serum, penicillin and streptomycin, β-mercaptoethanol, MEM nonessential amino acids, L-glutamine, and sodium pyruvate at 37°C in a humidified atmosphere with 5% CO2. O9-1 cells, a murine neural crest cell line (SCC049, Millipore Sigma), were maintained under embryonic stem cell medium (ES-101-B, Millipore Sigma) at 37°C in a humidified atmosphere with 5% CO2, as previously described (Yan et al., 2022).

2.4 Cell proliferation assay

MEFM or O9-1 cells were treated with a mimic for a negative control (4464061; mirVana miRNA mimic, Thermo Fisher Scientific), miR-383-3p, miR-6951-3p, miR-7116-3p, or miR-124-3p (4464066; mirVana miRNA mimic), or an inhibitor for a negative control (4464079; mirVana miRNA mimic), miR-383-3p, miR-6951-3p, miR-7116-3p or miR-124-3p (4464084; mirVana miRNA inhibitor), using the Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol. Cell proliferation was measured using the Cell Counting Kit 8 (Dojindo Molecular Technologies, Inc.) at 24, 48, and 72 h after each treatment (n = 6 per group), as previously described (Yan et al., 2022).

2.5 Immunocytochemistry

MEFM or O9-1 cells were seeded in an Ibidi 4-well slide (80426; Ibidi) at a density of 1 × 105 cells per well for MEFM cells and 5 × 104 cells per well for O9-1 cells, using 1 mL medium per well. Once the cell density reached 70%, the cells were treated with a mimic for negative control (4464061; mirVana miRNA mimic, Thermo Fisher Scientific), miR-28a-5p, miR-302a-3p, miR-302b-3p, or miR-302d-3p (4464066; mirVana miRNA mimic). Bromodeoxyuridine (BrdU) incorporation assays were conducted, as previously described (Suzuki et al., 2018b). A total of ten randomly selected fields from three independent experiments was used for the quantification of BrdU-positive cells. Immunocytochemical analysis for Ki-67 was performed using mouse monoclonal Ki-67 antibody (ab16667, Abcam, 1:600), as previously described (Suzuki et al., 2018b). Color images were obtained using a light microscope (BX43, Olympus) (n = 6 per group). Terminal 2′-deoxyuridine, 5′-triphosphate (dUTP) nick-end labeling (TUNEL) staining was performed using the Click-iT Plus TUNEL Assay (C10618, Molecular Probes), as previously described (Suzuki et al., 2018c). TUNEL-positive cells were quantified using five randomly selected fields from two independent experiments (total 10 fields). Fluorescent images were captured using a confocal microscope (Ti-C2, Nikon), while color images were obtained using a light microscope (BX43, Olympus).

2.6 Quantitative RT-PCR

MEFM or O9-1 cells were treated with either mimic or inhibitor for miR-383-3p, miR-6951-3p, miR-7116-3p, miR-124-3p, or a negative control, and gene expression was analyzed by quantitative RT-PCR (qRT-PCR), as previously described (n = 6 each group) (Yan et al., 2022). The PCR primers used in this study are listed in Supplementary Table S1.

2.7 TaqMan assay

Pregnant C57BL/6J mice were euthanized on E10.5, E11.5, and E12.5. The frontonasal processes and other relevant tissues were dissected from the embryos. These tissues were processed for total RNA extraction using the miRNeasey mini kit (217004, Qiagen) and converted to cDNA using the TaqMan microRNA reverse transcription kit (4366596, Thermo Fisher Scientific). miRNA expression levels were measured using the TaqMan system (Thermo Fisher Scientific) with probes for miR-124-3p (mmu480901_mir), miR-383-3p (mmu481150_mir), miR-6951-3p (mmu482850_mir), miR-7116-3p (mmu482410_mir), and U6 (001973), following the manufacturer’s instructions. A total of six samples from different litters were analyzed.

2.8 Statistical analysis

One-way analysis of variance (ANOVA) with the Tukey–Kramer post hoc test was used for multiple comparisons and two-way ANOVA was used for cell proliferation assays. Cell proliferation assays were analyzed using a two-way ANOVA. All experimental data were analyzed using the Prism software version 10 (GraphPad Software) and p-value <0.05 was considered statistically significant.

3 Results

3.1 Identification of a set of genes related to hypertelorism in mice

The information on genes related to hypertelorism in mice was collected through an MGI database search with reference literature validation. A total of 31 genes were confirmed, following full-text review, to be related to hypertelorism in mouse genetic models (Figure 1A; Table 1). The genes related to hypertelorism included either genes specific to hypertelorism (nonsyndromic hypertelorism genes) or those associated with broad craniofacial malformations (syndromic hypertelorism genes), caused by not only increased cell proliferation in the frontonasal region but also other craniofacial and/or brain anomalies. Genes were most significantly enriched in ocular hypertelorism (MP:0001300, enrichment FDR; 3.57 × 10−52) in the MGI clustering (Figure 1B; Supplementary Table S2). These genes were further grouped, according to function and pathway, with the KEGG pathway analysis; the genes were enriched in cancers, central carbon metabolism, EGFR tyrosine kinase inhibitor resistance, Gap junction, endocrine resistance, growth hormone synthesis, secretion and action, signaling pathways regulating pluripotency of stem cells, small GTPase RAP1 signaling pathway, phospholipase D signaling pathway, proteoglycans, miRNAs, regulation of actin cytoskeleton, RAS GTPase signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, and phosphoinositide 3-kinase (PI3K)-AKT signaling pathway (Figure 1C; Supplementary Table S3). Importantly, the KEGG pathway analysis highlighted miRNAs.

FIGURE 1

TABLE 1

GenesDescriptionMouse lineBroad craniofacial phenotypic presentationHypertelorism in humansReferences
Phenotype specific to the midfacial region
Alx4ALX homeobox 4Homozygous spontaneousFrontonasal dysplasia type 2; short nose, preaxial polydactyly, dorsal alopecia, bulging anterior cranium, open eyelidsYes [PMID: 34098755, 32216639, 29681084]PMID: 25673119
ArsbArylsulfatase BArsbY85H/Y85HCoarse facial features, short statureNo (coarse face) [PMID: 21930407]PMID: 36032399
Arsb−/−Mucopolysaccharidosis type VI; broad head and short snoutPMID: 8710849
Bmpr1aBone morphogenetic protein receptor, type 1AP0-Cre;caBmpr1aF/F (constitutively active)Isolated sagittal synostosis, short snoutYes, due to deletion of 10q22.3q23.2 (containing BMPR1A) [PMID: 20345475]PMID: 22773757, 11536076
Mpz-Cre;dnBmpr1aF/F (dominant negative)Midline cleft (83%) or short snout and hypertelorismPMID: 22773757
FrgfroggyHomozygous spontaneousShort snout, immature fusion of maxillary-premaxillary suturesNot in humansPMID: 26234751
GnasGNAS (guanine nucleotide binding protein, alpha stimulating) complex locusWnt1-Cre;GnasF/FDomed cranium, absence of nasal capsule, cleft palate, abnormal maxilla and mandibular bones (missing condylar and coronoid processes, hypoplastic)Yes [PMID: 15658617]PMID: 26859889
IduaIduronidase, alpha-LIdua−/−Mucopolysaccharidosis type I; broad face, short snout, dislocated hip, dysostosisNo (coarse face and low nasal bridge)PMID: 9097952
Lpar1Lysophosphatidic acid receptor 1Lpar1−/−Short stature, osteoporosisNoPMID: 21569876
Osx-Cre;Lpar1F/FOsteoporosis, thinner cortical bone, short femur; craniofacial phenotype not investigated-PMID: 32330664
PfasPhosphoribosylformylglycinamidine synthase (FGAR amidotransferase)Heterozygous spontaneous (Pfassofa/+)Upturned short snout, premature closure of cranial synchondrosis, micro/anophthalmiaNoPMID: 26234751
Tbx15T-box 15Tbx15de(H)/de(H);C57BL/6Jae/aeBroad nasal areaYes [PMID: 19068278]PMID: 15652702
Tbx15LacZ/LacZ (Tbx15−/−)Broad snout, short hypoplastic long bonesPMID: 15652702
Tet1Tet methylcytosine dioxygenase 1Tet1−/−Either midline cleft, bifid nose, or hypertelorism due to intracranial lipomaNoPMID: 26989192, 22246904
Tfap2aTranscription factor AP-2, alphaTfap2a-Cre;Tfap2aF/FShort concave nasal bone and snout, lack of interdigitation at the frontonasal suture, malocclusionNo [PMID: 19685247]PMID: 14975718
(Wnt1-Cre;Tfap2aF/Fdoes not have hypertelorism)
Tmem53Transmembrane protein 53Tmem531bin/1bin(1 bp T insertion)Hyperossification of calvaria, craniofacial hyperostosis, short limbsYes [PMID: 33824347]PMID: 33824347
Phenotype broadly in the craniofacial region
B3glctBeta-3-glucosyltransferaseB3glctD11-12/D11-12Peters plus syndrome; short snout, domed cranium, deviated nose (nasal asymmetry), soft tissue syndactylyYes [PMID: 23161355, 23889335]PMID: 31600785
BeyBulgy-eyeBey/+ (altered regulation of Fgf3 and Fgf4 expression)Crouzon syndrome; pansynostosis, domed cranium, short snout and maxillaSynthetic phenotypic maker (not in humans)PMID: 9626498
Chd8Chromodomain helicase DNA binding protein 8Chd8+/−Increased brain sizeYes [PMID: 24998929]PMID: 29668850
Crklv-crk avian sarcoma virus CT10 oncogene homolog-likeCrklsnoopy/snoopy (T>C at Chr 16: 17452790)Agnathia or hypognathia, maxillary hypoplasia, holoprosencephaly, microphthalmia or anophthalmiaYes, due to deletion of 22q11.2 (containing TBX11, CRKL1, and MAPK1) [PMID: 27629806, 27182748]PMID: 25565927
Crkl−/−22q11.2 deletion syndrome (DiGeorge syndrome); shorter/wider headPMID: 11242111
Dnmt3bDNA methyltransferase 3BPoint mutationImmunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome; short snoutYes [PMID: 21120685, 17893117]PMID: 16501171
Fgfr1Fibroblast growth factor receptor 1Fgfr1P252R/+Pfeifer syndrome; craniosynostosisYes [PMID: 32510873]PMID: 10942429
Fgfr2Fibroblast growth factor receptor 2Fgfr2C342Y/+ (gain-of function)Crouzon syndrome; craniosynostosis (coronal, lambdoid)No hypertelorism with p.C342Y variants [PMID: 28901406]PMID: 15459175, 15316116
Apert syndrome with p.P253R and p.S252W exhibit hypertelorism [PMID: 25867380]
Fgfr3Fibroblast growth factor receptor 3Fgfr3P244R/P244RMuenke syndrome; domed cranium, short and skewed snout, maxillary retrognathia, class III malocclusion, delayed ossification; no coronal synostosisYes [PMID: 32510873, 2133754]PMID: 19086028
Kif3aKinesin family member 3AWnt1Cre/+; Kif3afl/flHydrocephalus, isolated craniosynostosis, hypertelorism, and cleftingNoPMID: 24887031
KrasKirsten rat sarcoma viral oncogene homologKrasV14I/V14INoonan syndrome; short stature, short snout, wider/higher/shorter craniumYes [PMID: 32021610]PMID: 25359213
Lrp2Low density lipoprotein receptor-related protein 2Lrp2−/−Donnai-Barrow syndrome
Midline cleft, micro/anophthalmia, holoprosencephaly
Yes [PMID: 36777721, 34872573]PMID: 34463328
Mks1MKS transition zone complex subunit 1Mks1LacZ/LacZ (Mks1−/−)Meckel syndrome; holoprosencephaly, micrognathia (7/35), cleft lip (4/35), micro/anophthalmia (10/35); hypertelorism only 1/35NoPMID: 23454480
Ptch1Patched 1Ptch1−/−Gorlin-Goltz syndrome; lambdoid synostosis, domed craniumYes [PMID: 31533758, 2511723]PMID: 23897749
Ptch1mes/mesShort snout (short head)PMID: 8830098
Ptpn11 (a.k.a. Shp2)Protein tyrosine phosphatase, non-receptor type 11Ptpn11T468M/+Noonan syndrome; short headYes [PMID: 32164556, 19864201]PMID: 25288766, 21339643
Ptpn11Y279C/+LEOPARD syndrome or Noonan syndrome; short stature, slanted eye, flattened nasal bridgeYes [PMID: 18241070, 19768645]PMID: 21339643
Raf1v-raf-leukemia viral oncogene 1Raf1L613V/+Noonan syndrome; cranium with decreased height and increased widthYes [PMID: 20052757]PMID: 21339642
Rreb1ras responsive element binding protein 1Rreb1+/−Short snout, Noonan-spectrum of syndromesYes [PMID: 32938917]PMID: 32938917
Ror2Receptor tyrosine kinase-like orphan receptor 2Ror2−/−Robinow syndrome; midfacial hypoplasia, cleft palate, brachydactyly/polydactyly, short limbsYes [PMID: 35344616, 33496066]PMID: 14745966
Sh3pxd2bSH3 and PX domains 2BSh3pxd2b−/−Frank-Ter Haar syndrome; opened sagittal suture at 5 months of age, short cranium, micrognathia, thoracic kyphosis, lumbosacral lordosisYes [PMID: 35205281]PMID: 20137777
Sos1SOS Ras/Rac guanine nucleotide exchange factor 1Sos1E846K/+ and Sos1E846K/E846K (gain of function)Noonan syndrome 4; blunt short snoutYes [PMID: 27521173]PMID: 21041952

Genes associated with hypertelorism.

Next, to identify common BP, CC, and MF in the genes, we conducted a GO analysis and found that the hypertelorism-related genes were significantly enriched in regulation of cell proliferation, neurogenesis, and various tissues development in BP; kinesin II complex, axonal growth cone, plasma membrane raft, caveola, dendritic shaft, ciliary transition zone, receptor complex, dendrite, dendritic tree, neuronal cell body, and Golgi apparatus in CC; and FGF-activated receptor activity, adenylate cyclase activator activity, cyclase regulator activity, D1 dopamine receptor binding, FGF binding, peptide hormone receptor binding, enzyme activator activity, transmembrane receptor protein kinase activity, growth factor binding, purine ribonucleotide triphosphate binding in MF (Figure 1D; Supplementary Table S4).

3.2 Prediction for miRNAs in the regulation of genes related to hypertelorism

To predict miRNAs regulating genes related to hypertelorism, we performed bioinformatic analyses with these 31 hypertelorism-related genes using the miRTarbase, miRbase, MirDB, and TargetScan, and found that miR-383-3p potentially regulated the expression of 19 hypertelorism-related genes (Alx4, Arsb, B3glct, Chd8, Crkl, Fgfr1, Idua, Kif3a, Kras, Lpar1, Lrp2, Pfas, Ptch1, Ptpn11, Ror2, Rreb1, Sh3pxd2b, Tet1, and Tmem53; p = 5.05 × 10−5); miR-6951-3p potentially regulated the expression of 18 hypertelorism-related genes (Alx4, Bmpr1a, Chd8, Crkl, Dnmt3b, Fgfr1, Fgfr2, Gnas, Kif3a, Kras, Lpar1, Lrp2, Ptch1, Ror2, Rreb1, Sos1, Tet1, and Tfap2a; p = 4.96 × 10−4); miR-7116-3p potentially regulated the expression of 18 hypertelorism-related genes (Alx4, Bmpr1a, Chd8, Crkl, Dnmt3b, Fgfr1, Fgfr2, Gnas, Kif3a, Kras, Lpar1, Lrp2, Ptch1, Ror2, Rreb1, Sos1, Tet1, and Tfap2a; p = 1.08 × 10−6); and miR-124-3p potentially regulated the expression of 17 hypertelorism-related genes (Alx4, Bmpr1a, Chd8, Crkl, Fgfr1, Fgfr2, Gnas, Kif3a, Kras, Lpar1, Ptpn11, Raf1, Ror2, Rreb1, Sos1, Tbx15, and Tet1; p = 2.23 × 10−7) (Figure 1E; Table 2).

TABLE 2

miRNAp valueq value FDR bonferroniGene numberHypertelorism-associated genes
miR-383-3p5.05 × 10−52.92 × 10−119Alx4, Arsb, B3glct, Chd8, Crkl, Fgfr1, Idua, Kif3a, Kras, Lpar1, Lrp2, Pfas, Ptch1, Ptpn11, Ror2, Rreb1, Sh3pxd2b, Tet1, Tmem53
miR-6951-3p4.96 × 10−41.0018Alx4, Bmpr1a, Chd8, Crkl, Dnmt3b, Fgfr1, Fgfr2, Gnas, Kif3a, Kras, Lpar1, Lrp2, Ptch1, Ror2, Rreb1, Sos1, Tet1, Tfap2a
miR-7116-3p1.08 × 10−66.22 × 10−318Alx4, Bmpr1a, Chd8, Crkl, Dnmt3b, Fgfr1, Fgfr2, Gnas, Kif3a, Kras, Lpar1, Lrp2, Ptch1, Ror2, Rreb1, Sos1, Tet1, Tfap2a
miR-124-3p2.23 × 10−71.29 × 10−317Alx4, Bmpr1a, Chd8, Crkl, Fgfr1, Fgfr2, Gnas, Kif3a, Kras, Lpar1, Ptpn11, Raf1, Ror2, Rreb1, Sos1, Tbx15, Tet1
miR-669c-3p1.26 × 10−47.32 × 10−110Chd8, Crkl, Kif3a, Lpar1, Pfas, Ptch1, Rreb1, Tbx15, Tet1, Tmem53
miR-672-3p1.20 × 10−21.005Crkl, Fgfr1, Kif3a, Ptch1, Tmem53
miR-1231-5p1.25 × 10−31.003Dnmt3b, Tfap2a, Tmem53
miR-6905-5p6.81 × 10−41.002Dnmt3b, Tfap2a
miR-673-5p3.22 × 10−61.86 × 10−29Sh3pxd2b, Chd8, Crkl, Kif3a, Kras, Lrp2, Ptch1, Ror2, Rreb1
miR-7227-3p2.85 × 10−51.65 × 10−18Alx4, Bmpr1a, Fgfr1, Kif3a, Kras, Rreb1, Tet1, Tmem53
miR-875-3p1.58 × 10−59.16 × 10−28Alx4, Bmpr1a, Fgfr1, Kif3a, Kras, Rreb1, Tet1, Tmem53

Candidate miRNAs associated with hypertelorism.

3.3 Experimental validation for candidate miRNAs in cell proliferation and gene regulation

We hypothesized that miRNAs related to hypertelorism increase cell proliferation by regulating the expression of target genes during frontonasal development. To investigate this, we examined the functional significance of candidate miRNAs in cell proliferation in primary cells isolated from the developing E10.5 mouse frontonasal prominence (MEFM cells) and O9-1 cells treated with specific mimics for each miRNA. Our findings showed that overexpression of miR-383-3p or miR-6951-3p significantly enhanced cell proliferation (Figures 2A–E; Supplementary Figures S1A–E). We confirmed that these miRNA mimics did not induce apoptosis in these cells (Figure 2F; Supplementary Figure S1F). Conversely, specific inhibitors for miR-383-3p or miR-6951-3p did not affect cell proliferation in these cells (Figure 2G; Supplementary Figure S1G). Notably, overexpression of either miR-124-3p or miR-7116-3p was inhibited cell proliferation in both MEFM and O9-1 cells (Figure 2; Supplementary Figure S1); therefore, we excluded miR-124-3p and miR-7116-3p from our list of candidate miRNAs associated with hypertelorism. These miRNAs were expressed at relatively low levels during frontonasal development in C57BL6/J mice at E10.5-E12.5 (Figure 2H).

FIGURE 2

Next, we validated the predicted miRNA-gene regulation for miR-383-3p and miR-6951-3p in MEFM and O9-1 cells after treatment with their respective mimics. The miR-383-3p mimic significantly downregulated the expression of B3glct, Fgfr1, Ift27, Kif3a, Kras, Lpar1, Lrp2, Pfas, Ptch1, Ptpn11, and Tmem53, while the miR-6951-3p mimic significantly downregulated the expression of Bmpr1a, Chd8, Crkl, Dnmt3b, Fgfr2, Lpar1, Lrp2, Rreb1, Sos1, Tet1, and Tfap2a in these cells (Figures 3A,C; Supplementary Figures S2A,C). In contrast, the miR-383-3p inhibitor significantly upregulated the expression of B3glct, Fgfr1, Ift27, Kif3a, Kras, Lpar1, Ptch1, and Ptpn11. Similarly, the miR-6951-3p inhibitor significantly upregulated the expression of Bmpr1a, Chd8, Dnmt3b, Lpar1, Lrp2, Rreb1, and Tet1 in these cells (Figures 3B,D; Supplementary Figures S2B,D). Thus, miR-383-3p regulates the expression of B3glct, Fgfr1, Ift27, Kif3a, Kras, Lpar1, Ptch1, and Ptpn11 in a dose-dependent manner, whereas miR-6951-3p regulates the expression of Bmpr1a, Chd8, Dnmt3b, Lpar1, Lrp2, Rreb1, and Tet1. Notably, Lpar1 was an only gene regulated by both miR-383-3p and miR6951-3p.

FIGURE 3

4 Discussion

Craniofacial birth defects occur in a syndromic and/or nonsyndromic manner. Facial shape widely varies among individuals; therefore, an excessive difference from the mean or median is considered abnormal. Syndromic cases are caused mainly by monogenic and show a large effect size. On the other hand, nonsyndromic cases are caused by a complex interplay of genetic and epigenetic factors. These epigenetic factors, influenced by various conditions, including aging, nutrition, chemical/drug exposure, alcohol consumption, and smoking, contribute to developmental defects in humans and mice (Suzuki et al., 2016). Our bioinformatic analyses revealed that miR-383-3p and miR-6951-3p potentially regulate the expression of causative genes for hypertelorism in mice. Increasing evidence reveals miRNA functions under pathological conditions, but none are in FNP development. miR-383-3p is downregulated and induces cell growth in some types of cancer in humans (Jafarzadeh et al., 2022). It suppresses the epithelial-mesenchymal transition through the SHH-GLI family zinc finger 1 (GLI1) pathway in hepatocellular carcinoma (Chen et al., 2017) and through downregulation of the methylcrotonyl-CoA carboxylase subunit 1 (MCCC1) expression in malignant melanoma (Zhang et al., 2019) and gastric cancer (Huang et al., 2015). Interestingly, the expression of miR-383-3p is reduced in cardiomyocytes under a hypoxia/reoxygenation injury condition, leading to upregulation of the phosphatase and tensin homolog (PTEN)–phosphatidylinositol 3-kinase (PIK3) - AKT serine/threonine kinase signaling pathway, which increases apoptotic cell death (Zeng et al., 2022). By contrast, the function and expression of miR-6951-3p under physiological and pathological conditions are currently unknown. We found that cell proliferation was activated by overexpression of miR-383-3p and miR-6951-3p in MEFM and O9-1 cells. In contrast, although miR-124-3p and miR-7116-3p were predicted to be pathogenic miRNAs for hypertelorism, overexpression of miR-124-3p and miR-7116-3p inhibited cell proliferation in MEFM and O9-1 cells, suggesting that they are related to hypotelorism, an abnormally decreased distance between eyes. This observation is consistent with our previous findings in mouse lip mesenchymal cells (Suzuki et al., 2019), suggesting that induced miR-124-3p may lead to various craniofacial anomalies.

In this study, we curated genes associated with hypertelorism and predicted miRNAs that may regulate these genes. Our bioinformatic analyses identified miRNA-gene regulatory networks that could help uncover the causative mechanisms related to frontonasal anomalies. Our results show that several hypertelorism-related genes are uniquely and specifically regulated by miR-383-3p and miR-6951-3p. Among them, mice with a deficiency for Fgfr1 (Zhou et al., 2000), Fgfr2 (Eswarakumar et al., 2004), Kif3a (Liu et al., 2014), Kras (Hernandez-Porras et al., 2014), Ptch1 (Sweet et al., 1996), Rreb1 (Kent et al., 2020), Sos1 (Chen et al., 2010), and Tfap2a (Nelson and Williams, 2004) show excessive proliferation during midfacial development, resulting in hypertelorism, suggesting that mimics of miR-383-3p and miR-6951-3p activate cell proliferation through suppression of these genes. Although it remains unknown why only the frontonasal region grows excessively under some conditions, our study suggests that some miRNAs, which are either specifically or broadly expressed, play a crucial role in FNP development and hypertelorism. Among the target genes, Lpar1 was regulated by both miR-383-3p and miR-6951-3p. LPAR1 is widely expressed in multiple organs and embryonic tissues under physiological and pathological conditions (Boucharaba et al., 2004; Wu et al., 2019). Interestingly, mice deficient for Lpar1, one of the G-coupled lysophosphatidic acid (LPA) receptors, exhibit growth retardation, osteoporotic bones with low bone mass, calcification defects, and orbital hypertelorism (Gennero et al., 2011; Contos et al., 2000). LPA accelerates cell proliferation in cultured human skin-derived neural crest-like stem cells, and knockdown of Lpar1 suppresses their cell proliferation and migration (Liu et al., 2021). These results suggest that the role of Lrar1 and contribution to cell proliferation may depend on cell types. For example, it is known that LPA-LPAR signaling plays a role in bone development and osteogenic cell differentiation (Gennero et al., 2011; Alioli et al., 2020; David et al., 2014; Karagiosis and Karin, 2007). Taken together, increased cell proliferation may be caused by downregulation of multiple hypertelorism-related genes.

The KEGG analysis of hypertelorism-related genes revealed links to various cancers and carcinomas. Increased cell proliferation and migration are commonly observed in cancers characterized by rapid mass growth, and these processes are regulated by various growth factor signaling pathways, particularly FGF signaling (Turner and Grose, 2010). Our Gene Ontology (GO) results highlighted FGF signaling in this context. The pro-oncogene Raf1 and its downstream RAS-MAPK pathways, including Kras and Sos1, were involved in all the pathways identified in the KEGG analysis. These genes are critical for regulating cell proliferation and growth in cancers. Although the circumstances surrounding cancer and embryonic development differ, there are shared pathways that may influence cell growth and migration in hypertelorism.

FGF signaling is also linked to carbon metabolism, which was emphasized in our KEGG analysis. FGF21, along with its receptor FGFR1c, and FGF1 with its receptors FGFRs, play roles in regulating glucose and lipid metabolism and energy expenditure (Markan and Potthoff, 2016; Angelin et al., 2012; Nies et al., 2022). Because glucose metabolism is crucial for ATP generation, an essential energy source for all cellular functions (Mulukutla et al., 2016), it is crucial for growth and proliferation. Interestingly, the regulation of glucose and lipid metabolism is influenced by miRNAs (Agbu and Carthew, 2021). For example, miR-130a, miR-130b, and miR-152 can suppress both glycolysis and mitochondrial metabolism (Bobbs et al., 2012). Notably, treatment with SU5402, an FGFR inhibitor, increases the expression of miR-130b during the gustation stage in the primitive streak of chick embryos (Bobbs et al., 2012). This suggests that FGF signaling inhibition may reduce glucose metabolism by altering miRNA expression. It is possible that several miRNAs associated with hypertelorism influence cellular metabolism and functions through various pathways.

Our findings hold promise for the development of new therapeutic and preventive approaches for craniofacial anomalies, motivating us to continue our research for a better understanding of these complex conditions. However, there are some limitations in this study. First, the functional significance of each miRNA evaluated in MEFM and O9-1 cells remains unclear in vivo regarding frontonasal anomalies. This study also focuses solely on increased mesenchymal cell proliferation as a potential mechanism for hypertelorism; therefore, future research should explore other potential mechanisms, such as orbital movement toward the midline, osteogenic differentiation, and influences from other structures. Moreover, the expression patterns and timing of miRNAs should be assessed in vivo using in situ hybridization once the appropriate probes are available.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was approved by University of Michigan Institutional Animal Care and Use Committee. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

CI: Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – review and editing, Conceptualization, Writing – original draft. JI: Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review and editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by grants from the National Institute of Dental and Craniofacial Research, NIH (R01DE029818 and R01DE030122) to JI, and University of Michigan School of Dentistry faculty funds to JI.

Acknowledgments

The authors are grateful to Akiko Suzuki for fruitful discussion.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2025.1587052/full#supplementary-material

References

  • 1

    AgbuP.CarthewR. W. (2021). MicroRNA-mediated regulation of glucose and lipid metabolism. Nat. Rev. Mol. Cell Biol.22 (6), 425–438. 10.1038/s41580-021-00354-w

  • 2

    AlioliC. A.DemesmayL.Laurencin-DalacieuxS.BetonN.FarlayD.FolletH.et al (2020). Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification. Biochim. Biophys. Acta Mol. Cell Biol. Lipids1865 (8), 158715. 10.1016/j.bbalip.2020.158715

  • 3

    AngelinB.LarssonT. E.RudlingM. (2012). Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab.16 (6), 693–705. 10.1016/j.cmet.2012.11.001

  • 4

    BenjaminiY.DraiD.ElmerG.KafkafiN.GolaniI. (2001). Controlling the false discovery rate in behavior genetics research. Behav. Brain Res.125 (1-2), 279–284. 10.1016/s0166-4328(01)00297-2

  • 5

    BobbsA. S.SaarelaA. V.YatskievychT. A.AntinP. B. (2012). Fibroblast growth factor (FGF) signaling during gastrulation negatively modulates the abundance of microRNAs that regulate proteins required for cell migration and embryo patterning. J. Biol. Chem.287 (46), 38505–38514. 10.1074/jbc.M112.400598

  • 6

    BoucharabaA.SerreC. M.GresS.Saulnier-BlacheJ. S.BordetJ. C.GuglielmiJ.et al (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest114 (12), 1714–1725. 10.1172/JCI22123

  • 7

    ChenJ. S.LiangL. L.XuH. X.ChenF.ShenS. L.ChenW.et al (2017). miR-338-3p inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma cells. Oncotarget8 (42), 71418–71429. 10.18632/oncotarget.10138

  • 8

    ChenP. C.WakimotoH.ConnerD.ArakiT.YuanT.RobertsA.et al (2010). Activation of multiple signaling pathways causes developmental defects in mice with a noonan syndrome-associated Sos1 mutation. J. Clin. Invest120 (12), 4353–4365. 10.1172/JCI43910

  • 9

    ClaesP.RoosenboomJ.WhiteJ. D.SwigutT.SeroD.LiJ.et al (2018). Genome-wide mapping of global-to-local genetic effects on human facial shape. Nat. Genet.50 (3), 414–423. 10.1038/s41588-018-0057-4

  • 10

    CobourneM. T.XavierG. M.DepewM.HaganL.SealbyJ.WebsterZ.et al (2009). Sonic hedgehog signalling inhibits palatogenesis and arrests tooth development in a mouse model of the nevoid basal cell carcinoma syndrome. Dev. Biol.331 (1), 38–49. 10.1016/j.ydbio.2009.04.021

  • 11

    CohenM. M.Jr.Richieri-CostaA.Guion-AlmeidaM. L.SaavedraD. (1995). Hypertelorism: interorbital growth, measurements, and pathogenetic considerations. Int. J. Oral Maxillofac. Surg.24 (6), 387–395. 10.1016/s0901-5027(05)80465-5

  • 12

    ContosJ. J.FukushimaN.WeinerJ. A.KaushalD.ChunJ. (2000). Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. U. S. A.97 (24), 13384–13389. 10.1073/pnas.97.24.13384

  • 13

    DavidM.Machuca-GayetI.KikutaJ.OttewellP.MimaF.LeblancR.et al (2014). Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J. Biol. Chem.289 (10), 6551–6564. 10.1074/jbc.M113.533232

  • 14

    EswarakumarV. P.HorowitzM. C.LocklinR.Morriss-KayG. M.LonaiP. (2004). A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc. Natl. Acad. Sci. U. S. A.101 (34), 12555–12560. 10.1073/pnas.0405031101

  • 15

    GeS. X.JungD.YaoR. (2020). ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics36 (8), 2628–2629. 10.1093/bioinformatics/btz931

  • 16

    GenneroI.Laurencin-DalicieuxS.Conte-AuriolF.Briand-MesangeF.LaurencinD.RueJ.et al (2011). Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone49 (3), 395–403. 10.1016/j.bone.2011.04.018

  • 17

    Hernandez-PorrasI.FabbianoS.SchuhmacherA. J.AicherA.CanameroM.CamaraJ. A.et al (2014). K-RasV14I recapitulates Noonan syndrome in mice. Proc. Natl. Acad. Sci. U. S. A.111 (46), 16395–16400. 10.1073/pnas.1418126111

  • 18

    HuangH. Y.LinY. C.LiJ.HuangK. Y.ShresthaS.HongH. C.et al (2020). miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res.48 (D1), D148–D154. 10.1093/nar/gkz896

  • 19

    HuangN.WuZ.LinL.ZhouM.WangL.MaH.et al (2015). MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget6 (17), 15222–15234. 10.18632/oncotarget.3835

  • 20

    IwayaC.SuzukiA.IwataJ. (2023). MicroRNAs and gene regulatory networks related to cleft lip and palate. Int. J. Mol. Sci.24 (4), 3552. 10.3390/ijms24043552

  • 21

    JafarzadehA.NooriM.SarrafzadehS.Tamehri ZadehS. S.NematiM.ChatrabnousN.et al (2022). MicroRNA-383: a tumor suppressor miRNA in human cancer. Front. Cell Dev. Biol.10, 955486. 10.3389/fcell.2022.955486

  • 22

    KaragiosisS. A.KarinN. J. (2007). Lysophosphatidic acid induces osteocyte dendrite outgrowth. Biochem. Biophys. Res. Commun.357 (1), 194–199. 10.1016/j.bbrc.2007.03.121

  • 23

    KentO. A.SahaM.CoyaudE.BurstonH. E.LawN.DadsonK.et al (2020). Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes. Nat. Commun.11 (1), 4673. 10.1038/s41467-020-18483-9

  • 24

    KimonisV.GoldJ. A.HoffmanT. L.PanchalJ.BoyadjievS. A. (2007). Genetics of craniosynostosis. Semin. Pediatr. Neurol.14 (3), 150–161. 10.1016/j.spen.2007.08.008

  • 25

    KnolM. J.PawlakM. A.LamballaisS.TerzikhanN.HoferE.XiongZ.et al (2022). Genetic architecture of orbital telorism. Hum. Mol. Genet.31 (9), 1531–1543. 10.1093/hmg/ddab334

  • 26

    LiuB.ChenS.JohnsonC.HelmsJ. A. (2014). A ciliopathy with hydrocephalus, isolated craniosynostosis, hypertelorism, and clefting caused by deletion of Kif3a. Reprod. Toxicol.48, 88–97. 10.1016/j.reprotox.2014.05.009

  • 27

    LiuJ.RebeccaV. W.KossenkovA. V.ConnellyT.LiuQ.GutierrezA.et al (2021). Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Res.81 (20), 5230–5241. 10.1158/0008-5472.CAN-20-1496

  • 28

    LuoW.BrouwerC. (2013). Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics29 (14), 1830–1831. 10.1093/bioinformatics/btt285

  • 29

    MarkanK. R.PotthoffM. J. (2016). Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis. Semin. Cell Dev. Biol.53, 85–93. 10.1016/j.semcdb.2015.09.021

  • 30

    MulukutlaB. C.YongkyA.LeT.MashekD. G.HuW. S. (2016). Regulation of glucose metabolism - a perspective from cell bioprocessing. Trends Biotechnol.34 (8), 638–651. 10.1016/j.tibtech.2016.04.012

  • 31

    MyersL.AnderlidB. M.NordgrenA.LundinK.Kuja-HalkolaR.TammimiesK.et al (2020). Clinical versus automated assessments of morphological variants in twins with and without neurodevelopmental disorders. Am. J. Med. Genet. A182 (5), 1177–1189. 10.1002/ajmg.a.61545

  • 32

    NelsonD. K.WilliamsT. (2004). Frontonasal process-specific disruption of AP-2alpha results in postnatal midfacial hypoplasia, vascular anomalies, and nasal cavity defects. Dev. Biol.267 (1), 72–92. 10.1016/j.ydbio.2003.10.033

  • 33

    NiesV. J. M.StruikD.LiuS.LiuW.KruitJ. K.DownesM.et al (2022). Autocrine FGF1 signaling promotes glucose uptake in adipocytes. Proc. Natl. Acad. Sci. U. S. A.119 (40), e2122382119. 10.1073/pnas.2122382119

  • 34

    RioloG.CantaraS.MarzocchiC.RicciC. (2020). miRNA targets: from prediction tools to experimental validation. Methods Protoc.4 (1), 1. 10.3390/mps4010001

  • 35

    SeroD.ZaidiA.LiJ.WhiteJ. D.ZarzarT. B. G.MarazitaM. L.et al (2019). Facial recognition from DNA using face-to-DNA classifiers. Nat. Commun.10 (1), 2557. 10.1038/s41467-019-10617-y

  • 36

    SomP. M.NaidichT. P. (2013). Illustrated review of the embryology and development of the facial region, part 1: early face and lateral nasal cavities. AJNR Am. J. Neuroradiol.34 (12), 2233–2240. 10.3174/ajnr.A3415

  • 37

    SuzukiA.AbdallahN.GajeraM.JunG.JiaP.ZhaoZ.et al (2018a). Genes and microRNAs associated with mouse cleft palate: a systematic review and bioinformatics analysis. Mech. Dev.150, 21–27. 10.1016/j.mod.2018.02.003

  • 38

    SuzukiA.MinamideR.IwataJ. (2018b). The role of acetyltransferases for the temporal-specific accessibility of beta-catenin to the myogenic gene locus. Sci. Rep.8 (1), 15057. 10.1038/s41598-018-32888-z

  • 39

    SuzukiA.MinamideR.IwataJ. (2018c). WNT/β-catenin signaling plays a crucial role in myoblast fusion through regulation of Nephrin expression during development. Development145 (23), dev168351. 10.1242/dev.168351

  • 40

    SuzukiA.SanganiD. R.AnsariA.IwataJ. (2016). Molecular mechanisms of midfacial developmental defects. Dev. Dyn.245 (3), 276–293. 10.1002/dvdy.24368

  • 41

    SuzukiA.YoshiokaH.SummakiaD.DesaiN. G.JunG.JiaP.et al (2019). MicroRNA-124-3p suppresses mouse lip mesenchymal cell proliferation through the regulation of genes associated with cleft lip in the mouse. BMC Genomics20 (1), 852. 10.1186/s12864-019-6238-4

  • 42

    SweetH. O.BronsonR. T.DonahueL. R.DavissonM. T. (1996). Mesenchymal dysplasia: a recessive mutation on chromosome 13 of the mouse. J. Hered.87 (2), 87–95. 10.1093/oxfordjournals.jhered.a022981

  • 43

    TurnerN.GroseR. (2010). Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer10 (2), 116–129. 10.1038/nrc2780

  • 44

    WhiteJ. D.IndencleefK.NaqviS.EllerR. J.HoskensH.RoosenboomJ.et al (2021). Insights into the genetic architecture of the human face. Nat. Genet.53 (1), 45–53. 10.1038/s41588-020-00741-7

  • 45

    WuX.MaY.SuN.ShenJ.ZhangH.WangH. (2019). Lysophosphatidic acid: its role in bone cell biology and potential for use in bone regeneration. Prostagl. Other Lipid Mediat143, 106335. 10.1016/j.prostaglandins.2019.106335

  • 46

    XiongZ.DankovaG.HoweL. J.LeeM. K.HysiP. G.de JongM. A.et al (2019). Novel genetic loci affecting facial shape variation in humans. Elife8, e49898. 10.7554/eLife.49898

  • 47

    YanF.SimonL. M.SuzukiA.IwayaC.JiaP.IwataJ.et al (2022). Spatiotemporal MicroRNA-Gene expression network related to orofacial clefts. J. Dent. Res.101 (11), 1398–1407. 10.1177/00220345221105816

  • 48

    ZengH.LiY.LiuX.LiX.ZhouT.CaoS.et al (2022). Overexpression of miR-383-3p protects cardiomyocytes against hypoxia/reoxygenation injury via regulating PTEN/PI3K/AKT signal pathway. J. Biochem. Mol. Toxicol.36 (12), e23205. 10.1002/jbt.23205

  • 49

    ZhangC.LiH.WangJ.ZhangJ.HouX. (2019). MicroRNA-338-3p suppresses cell proliferation, migration and invasion in human malignant melanoma by targeting MACC1. Exp. Ther. Med.18 (2), 997–1004.

  • 50

    ZhouY. X.XuX.ChenL.LiC.BrodieS. G.DengC. X. (2000). A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum. Mol. Genet.9 (13), 2001–2008. 10.1093/hmg/9.13.2001

Summary

Keywords

craniofacial development, MicroRNAs, hypertelorism, birth defects, cranial neural crest cells

Citation

Iwaya C and Iwata J (2025) miR-383-3p and miR-6951-3p activate cell proliferation through the regulation of genes related to hypertelorism. Front. Cell Dev. Biol. 13:1587052. doi: 10.3389/fcell.2025.1587052

Received

03 March 2025

Accepted

15 July 2025

Published

24 July 2025

Volume

13 - 2025

Edited by

Michael Schubert, UMR7009 Laboratoire de Biologie du Développement de Villefranche sur Mer, France

Reviewed by

Tianjin Shen, University of Texas Southwestern Medical Center, United States

Chantal Thibert, Centre National de la Recherche Scientifique (CNRS), France

Updates

Copyright

*Correspondence: Junichi Iwata,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics